When you are diagnosed with a drug resistant disease, the best way to protect yourself is to take the drug prescribed.
However, as drug resistance is often a precursor to a deadly condition, some people are reluctant to take a new drug, even if the benefits are worth it.
A new drug called VINPOCETINE has been hailed as a cure for many people with drug-resistance, with researchers predicting its potential for a cure as early as next year.
Read moreWhat is VINpocETINE?VINPocETine is a drug developed by Pfizer in partnership with the US government.
It has been shown to be safe and effective in preventing and treating drug resistance.
Pfizer says it is the first of its kind to be licensed for use in humans, and it has already proven effective in people who have had prior resistance to the drug.
What do you need to know about VIN, VINPs efficacy and safety?VIPTECH is a clinical trial and trial-managed clinical trial of VIN POT 1 and POT 2 to treat the first phase of Pfizer’s drug-induced drug resistance trial (PID-2) with VIN1.
The study is expected to end in the second half of 2019.
Pfizer said it plans to conduct a second phase of VIND-POT 1 with VIND2 in the future.
“Pfizers efficacy in this phase is consistent with clinical trials in humans with other types of resistance,” Pfizer said in a statement.
What is the treatment for drug-refreshing resistance?
The FDA approved VIN-POC in 2017 and Pfizer is working with the FDA to make it available for use.
VIN is currently being tested in people with previously resistant drug-reaction.
Pfizers clinical trial, which started in 2017, will continue for at least another six years, Pfizer added.
If you have an emergency or urgent health situation and require immediate medical attention, call 911 immediately.